Jeffrey J. Wallin

6.1k total citations
60 papers, 2.8k citations indexed

About

Jeffrey J. Wallin is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, Jeffrey J. Wallin has authored 60 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Immunology, 19 papers in Molecular Biology and 16 papers in Oncology. Recurrent topics in Jeffrey J. Wallin's work include PI3K/AKT/mTOR signaling in cancer (11 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Immune Cell Function and Interaction (8 papers). Jeffrey J. Wallin is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (11 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Immune Cell Function and Interaction (8 papers). Jeffrey J. Wallin collaborates with scholars based in United States, Canada and Germany. Jeffrey J. Wallin's co-authors include William C. Sha, Priti S. Hegde, Christoph Mancao, Marcia Belvin, Deepak Sampath, Wei Wei Prior, Lori S. Friedman, Marian Elliott Koshland, Kyle A. Edgar and Linda Liang and has published in prestigious journals such as Science, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Jeffrey J. Wallin

56 papers receiving 2.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jeffrey J. Wallin United States	28	1.2k	1.1k	829	483	252	60	2.8k
Elie Marcheteau France	12	1.5k 1.3×	1.0k 0.9×	594 0.7×	466 1.0×	239 0.9×	20	2.4k
Ines Gütgemann Germany	25	1.1k 0.9×	1.2k 1.0×	1.3k 1.6×	332 0.7×	168 0.7×	60	3.0k
Ann Cleverly United States	25	1.5k 1.3×	530 0.5×	1.3k 1.6×	333 0.7×	224 0.9×	54	2.6k
Joe Yeong Singapore	26	1.5k 1.2×	1.1k 1.0×	763 0.9×	450 0.9×	145 0.6×	94	2.7k
Yu Kato Japan	15	1.8k 1.5×	1.5k 1.3×	472 0.6×	348 0.7×	249 1.0×	30	2.7k
Mark D. McKee United States	18	1.6k 1.3×	951 0.8×	744 0.9×	335 0.7×	361 1.4×	46	2.6k
Magali Terme France	25	2.4k 2.0×	2.5k 2.2×	1.3k 1.6×	617 1.3×	305 1.2×	51	4.4k
Elizabeth Stankevich United States	15	2.4k 2.0×	1.3k 1.1×	416 0.5×	665 1.4×	188 0.7×	39	2.9k
Yvonne M. Saenger United States	26	1.3k 1.1×	921 0.8×	500 0.6×	273 0.6×	71 0.3×	82	2.2k
Diana F. Hausman United States	18	584 0.5×	472 0.4×	538 0.6×	310 0.6×	126 0.5×	40	1.6k

Countries citing papers authored by Jeffrey J. Wallin

Since Specialization

Citations

This map shows the geographic impact of Jeffrey J. Wallin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey J. Wallin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey J. Wallin more than expected).

Fields of papers citing papers by Jeffrey J. Wallin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey J. Wallin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey J. Wallin. The network helps show where Jeffrey J. Wallin may publish in the future.

Co-authorship network of co-authors of Jeffrey J. Wallin

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey J. Wallin. A scholar is included among the top collaborators of Jeffrey J. Wallin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey J. Wallin. Jeffrey J. Wallin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bailón, Lucía, José Ramón Arribas, Adrián Curran, et al.. (2025). Predictors of virological outcomes after analytical interruption of antiretroviral therapy and HTI vaccination in early treated people with HIV-1._. Communications Medicine. 6(1). 11–11.

Allweiss, Lena, Vithika Suri, Jeffrey J. Wallin, et al.. (2024). Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies. Journal of Hepatology. 80(6). 882–891. 18 indexed citations

Riddler, Sharon A., Constance A. Benson, Steven G. Deeks, et al.. (2024). A Pooled Analysis of Eight Clinical Studies Suggests a Link Between Influenza-Like Symptoms and Pharmacodynamics of the Toll-Like Receptor-7 Agonist Vesatolimod. Infectious Diseases and Therapy. 13(11). 2285–2299. 1 indexed citations

Bauer, Rebecca N., Anastasia Teterina, Haridha Shivram, et al.. (2023). Prognostic value of severe acute respiratory syndrome coronavirus‐2 viral load and antibodies in patients hospitalized with COVID‐19. Clinical and Translational Science. 16(6). 1049–1062. 6 indexed citations

Allweiss, Lena, Vithika Suri, Jeffrey J. Wallin, et al.. (2023). Strong decline of intrahepatic HDV markers and signs of liver inflammation after 48 weeks of treatment with Bulevirtide in chronic hepatitis D patients: Combined intrahepatic results from the clinical trials MYR203 and MYR301. Zeitschrift für Gastroenterologie. 61(1). e50–e51. 1 indexed citations

Kim, Samuel, Jeffrey J. Wallin, Yanal Ghosheh, et al.. (2023). Efficacy of antiviral therapy and host–virus interactions visualised using serial liver sampling with fine-needle aspirates. JHEP Reports. 5(9). 100817–100817. 13 indexed citations

Gane, Edward, Hyung Joon Kim, Kumar Visvanathan, et al.. (2021). Safety, Pharmacokinetics, and Pharmacodynamics of the Oral TLR8 Agonist Selgantolimod in Chronic Hepatitis B. Hepatology. 74(4). 1737–1749. 30 indexed citations

Liu, Stephen V., D. Ross Camidge, Scott Gettinger, et al.. (2018). Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non–small-cell lung cancer. European Journal of Cancer. 101. 114–122. 38 indexed citations

Sullivan, Ryan J., René González, Karl D. Lewis, et al.. (2017). Atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in BRAF^V600-mutant metastatic melanoma (mel): Updated safety and clinical activity.. Journal of Clinical Oncology. 35(15_suppl). 3063–3063. 41 indexed citations

10.

Hegde, Priti S., Jeffrey J. Wallin, & Christoph Mancao. (2017). Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics. Seminars in Cancer Biology. 52(Pt 2). 117–124. 322 indexed citations

11.

Osswald, Matthias, Jonas Blaes, Yunxiang Liao, et al.. (2016). Impact of Blood–Brain Barrier Integrity on Tumor Growth and Therapy Response in Brain Metastases. Clinical Cancer Research. 22(24). 6078–6087. 88 indexed citations

12.

Hwu, Patrick, Omid Hamid, René González, et al.. (2016). Preliminary safety and clinical activity of atezolizumab combined with cobimetinib and vemurafenib in BRAF V600-mutant metastatic melanoma. Annals of Oncology. 27. vi380–vi380. 26 indexed citations

13.

Wallin, Jeffrey J., Jane Guan, Wei Wei Prior, et al.. (2012). GDC-0941, a Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death In Vitro and In Vivo. Clinical Cancer Research. 18(14). 3901–3911. 73 indexed citations

14.

Wallin, Jeffrey J., Jane Guan, Kyle A. Edgar, et al.. (2012). Active PI3K Pathway Causes an Invasive Phenotype Which Can Be Reversed or Promoted by Blocking the Pathway at Divergent Nodes. PLoS ONE. 7(5). e36402–e36402. 39 indexed citations

15.

Edgar, Kyle A., Jeffrey J. Wallin, Megan Berry, et al.. (2010). Isoform-Specific Phosphoinositide 3-Kinase Inhibitors Exert Distinct Effects in Solid Tumors. Cancer Research. 70(3). 1164–1172. 94 indexed citations

16.

Wallin, Jeffrey J., Kyle A. Edgar, Jane Guan, Lori S. Friedman, & Marcia Belvin. (2009). Abstract #3392: Transient pAkt increase after chemo exposure predicts strength of synergy for combinations of the PI3K inhibitor GDC-0941 and chemotherapeutics. Cancer Research. 69. 3392–3392. 1 indexed citations

17.

Wallin, Jeffrey J., et al.. (2001). Enhancement of CD8+ T Cell Responses by ICOS/B7h Costimulation. The Journal of Immunology. 167(1). 132–139. 132 indexed citations

18.

Zwollo, Patty, et al.. (1998). The Transcription Factor NF-κB/p50 Interacts with the blkGene during B Cell Activation. Journal of Biological Chemistry. 273(29). 18647–18655. 29 indexed citations

19.

Hurwitz, Arthur A., et al.. (1998). Enhancement of the anti-tumor immune response using a combination of interferon-γ and B7 expression in an experimental mammary carcinoma. International Journal of Cancer. 77(1). 107–113. 37 indexed citations

20.

Weinberg, Andrew D., Dennis Bourdette, Timothy J. Sullivan, et al.. (1996). Selective depletion of myelin–reactive T cells with the anti–OX–40 antibody ameliorates autoimmune encephalomyelitis. Nature Medicine. 2(2). 183–189. 130 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact